Posted by admin on Jun 23rd, 2022
INVO Bioscience (NASDAQ:INVO – Get Rating) and NuVasive (NASDAQ:NUVA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.
INVO Bioscience has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for INVO Bioscience and NuVasive, as provided by MarketBeat.com.
INVO Bioscience currently has a consensus target price of $2.50, suggesting a potential upside of 214.66%. NuVasive has a consensus target price of $63.78, suggesting a potential upside of 29.50%. Given INVO Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe INVO Bioscience is more favorable than NuVasive.
This table compares INVO Bioscience and NuVasive’s net margins, return on equity and return on assets.
21.7% of INVO Bioscience shares are owned by institutional investors. 7.6% of INVO Bioscience shares are owned by insiders. Comparatively, 0.5% of NuVasive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares INVO Bioscience and NuVasive’s top-line revenue, earnings per share (EPS) and valuation.
INVO Bioscience has higher earnings, but lower revenue than NuVasive.
INVO Bioscience Company Profile (Get Rating)
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
NuVasive Company Profile (Get Rating)
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Infineon Technologies AG (OTCMKTS:IFNNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Tiptree (NASDAQ:TIPT) Stock Crosses Below Two Hundred Day Moving Average of $12.27